Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
Sponsor: Bristol-Myers Squibb
Summary
The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US
Official title: Long-Term Real-World Outcomes Among Patients With Programmed Death-Ligand 1 (PD-L1) <1% Metastatic Non-Small Cell Lung Cancer (mNSCLC) Treated With First-Line (1l) Nivolumab + Ipilimumab + 2 Cycles Of Chemotherapy (NIC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2024-10-24
Completion Date
2025-06-30
Last Updated
2025-06-17
Healthy Volunteers
No
Conditions
Interventions
nivolumab + ipilimumab
First-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC)
Locations (1)
Cardinal Health
Dublin, Ohio, United States